文献速递耳科与耳神经小儿耳鼻咽喉

外显子组测序用于孤立性先天性耳聋的成本效果分析

Exome Sequencing for Isolated Congenital Hearing Loss: A Cost-Effectiveness Analysis.
PubMed 文献 · Laryngoscope · 2020-12-31

本研究从澳大利亚医疗系统视角,采用18年时间跨度,通过决策树模型比较外显子组测序与标准诊疗用于孤立性先天性耳聋婴儿的成本效果。结果显示外显子组测序每名儿童增加成本1000澳元,每100名受检儿童多诊断30例,增量成本效果比为每增加一例诊断3333澳元,平均社会支付意愿为每名受检儿童4600澳元,净收益为3600澳元,确定性及概率敏感性分析均证实其成本效果。

要点

  • 外显子组测序每100名患儿可多诊断30例,增量成本效果比为3333澳元/额外诊断。
  • 社会支付意愿为每名受检儿童4600澳元,净收益为3600澳元。
  • 建议对孤立性先天性耳聋婴儿提供公平的外显子组测序资助。

核心结论

  • 外显子组测序通过提高诊断率并优化诊疗流程,在孤立性先天性耳聋中具有成本效果。

研究设计与样本

  • 采用决策树模型,从澳大利亚医疗系统视角进行增量成本效果和成本效益分析,时间跨度为18年。

主要发现

  • 外显子组测序每名儿童增加成本1000澳元,每100名受检儿童增加30例诊断。
  • 增量成本效果比为每增加一例诊断3333澳元。
  • 平均社会支付意愿为每名受检儿童4600澳元,净收益为3600澳元。
  • 确定性和概率敏感性分析均证实外显子组测序具有成本效果。

临床怎么用

  • 对于孤立性先天性耳聋婴儿,可考虑外显子组测序以增加诊断率并减少或停止不必要的诊断检查。
  • 建议为外显子组测序提供公平的资助。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES/HYPOTHESIS: To assess the relative cost-effectiveness of exome sequencing for isolated congenital deafness compared with standard care. STUDY DESIGN: Incremental cost-effectiveness and cost-benefit analyses were undertaken from the perspective of the Australian healthcare system using an 18-year time horizon. METHODS: A decision tree was used to model the costs and outcomes associated with exome sequencing and standard care for infants presenting with isolated congenital deafness. RESULTS: Exome sequencing resulted in an incremental cost of AU$1,000 per child and an additional 30 diagnoses per 100 children tested. The incremental cost-effectiveness ratio was AU$3,333 per additional diagnosis. The mean societal willingness to pay for exome sequencing was estimated at AU$4,600 per child tested relative to standard care, resulting in a positive net benefit of AU$3,600. Deterministic and probabilistic sensitivity analyses confirmed the cost-effectiveness of exome sequencing. CONCLUSIONS: Our findings demonstrate the cost-effectiveness of exome sequencing in congenital hearing loss, through increased diagnostic rate and consequent improved process of care by reducing or ceasing diagnostic investigation or facilitating targeted further investigation. We recommend equitable funding for exome sequencing in infants presenting with isolated congenital hearing loss. LEVEL OF EVIDENCE: N/A. Laryngoscope, 131:E2371-E2377, 2021.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Downie L, Amor DJ, Halliday J, et al. Exome Sequencing for Isolated Congenital Hearing Loss: A Cost-Effectiveness Analysis. Laryngoscope. 2020. PMID: 33382469. doi:10.1002/lary.29356

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。